Overexpression of the Insulin Receptor Isoform A Promotes Endometrial Carcinoma Cell Growth

Chun-Fang Wang*, Guo Zhang*, Li-Jun Zhao*, Wen-Juan Qi, Xiao-Ping Li, Jian-Liu Wang, Li-Hui Wei*

Department of Obstetrics and Gynecology, Peking University People’s Hospital, Peking University, Beijing, China

Abstract

Epidemiological studies have demonstrated that type 2 diabetes mellitus (T2DM) and hyperinsulinemia are associated closely with endometrial carcinoma risk, although the molecular mechanism remains unclear. Insulin receptor isoform A expression is upregulated in many cancer cells and tissues, which suggests that IR-A-mediated signaling pathways may have important implications for cancer pathogenesis. We measured the expression of insulin receptor isoforms (IR-A and IR–B in the normal endometrium tissues, the endometrial carcinoma tissues and the endometrial carcinoma cell lines. We found that the total insulin receptor (IR) and IR-A expression mRNA levels and the ratio of IR-A to total IR in endometrial carcinoma specimens were significantly higher than them in control endometrial tissue specimens (P<0.05). Further analysis indicated that the tendency was more prominently in patients with T2DM. IR-A mRNA was differentially expressed in four endometrial carcinoma cell lines (Ishikawa, KLE, RL95-2 and HEC-1-A. RL95-2 cells have a low endogenous IR-A expression, and these were used to construct a stable cell line overexpressing IR-A. We found that IR-A overexpression significantly increased cell proliferation, the proportion of cells in S phase, activation of the Akt pathway and tumorigenicity of xenografts in nude mice. In contrast, there was no significant difference in the percentage of apoptotic cells between cells overexpressing IR-A and control cells. Moreover, levels of phosphorylated ERK1/2 protein were significantly decreased in cells overexpressing IR-A relative to controls. These findings reveal the pivotal role of IR-A in endometrial cancer carcinogenesis, and suggest that the association of elevated IR-A levels with cell proliferation and tumorigenicity may be causally linked to its effect on the proportion of cells in S phase and the activation of the Akt pathway.

Introduction

Endometrial cancer is the third most common malignancy of the female genital tract reported in China. The incidence and mortality rate of endometrial carcinoma has increased in recent years [1]. An improved understanding of the factors regulating endometrial cancer cell growth should lead to better treatment options.

The insulin receptor (IR) belongs to a subfamily of receptor tyrosine kinases that includes the insulin-like growth factor (IGF) 1 receptor(IGF-1R) and the insulin-receptor-related receptor. Members of this family of receptors are tetrameric proteins consisting of two extracellular α-subunits and two transmembrane β-subunits linked by disulfide bonds [2]. The human IR is encoded by a large single insulin receptor gene comprising 22 exons and the protein is expressed as two different isoforms that differ at the carboxyl terminus of the α-subunits by 12 amino acids [3]. The presence (IR–B, or IR exon 11+) or absence (IR-A, or exon 11-) of these residues alters the functional properties of the isoform. IR–B is a classical IR that regulates glucose uptake. In contrast, IR-A has potent mitogenic and anti-apoptotic functions and plays a key role in cell proliferation [4].

Expression of the insulin receptor isoform A (IR-A) has been predominantly detected in cancers of the breast, lung, colon [5], thyroid [6], ovaries [7], and smooth and striated muscle [8]. IR-A expression is upregulated in many cancer cells and tissues, which suggests that IR-A-mediated signaling pathways may have important implications for cancer pathogenesis [9]. Understanding the IR-A expression and function in the endometrial cancer tissues and cells is critical for advancing our knowledge of endometrial cancer biology, and could lead to the development of novel tumor-specific therapies.
The present study aims to determine the expression of IR-A in the normal endometrium tissues, the endometrial carcinoma tissues, and the cell lines. endometrial carcinoma tissues, and endometrial carcinoma cell lines (Ishikawa, KLE, HEC-1-A and RL95-2, which was named RL95-2-CON in this paper). Then we explored the role of IR-A in human endometrial cancer development.

**Results**

**Expression of insulin receptor isoforms and IGF-2 in endometrial cancer cell lines and tissues**

To assess expression of IR and IGF-2 in human endometrial cancer cell lines, reverse transcription polymerase chain reaction (RT-PCR) and Real time RT-PCR were performed using RNA from the HEC-1-A, Ishikawa, KLE, RL95-2-CON endometrial cancer cell lines, positive control Liver cancer cell line Hep-G2 and breast cancer cell line MCF-7. RT-PCR shown that IR-A, IR-B and IGF-2 are differentially expressed in HEC-1-A, Ishikawa, KLE and RL95-2-CON endometrial cancer cells(Figure 1A). The real time RT-PCR results shown the relative expression levels of IR-A and total IR in four endometrial cancer cells (Figure 1B). The ratio of IR-A/ IR in endometrial cancer cell lines from real-time RT-PCR results. D. ELISA quantitation of IGF-2 protein secreted by RL95-2–CON, RL95-2–IR-A, KLE, HEC-1-A and Ishikawa cells.

doi: 10.1371/journal.pone.0069001.g001
endometrial tissue samples (35%) and the electrophoretic assay of representative examples was shown in Figure 2. Real time RT-PCR results of tissue specimens was shown in table 1, The total IR and IR-A expression levels and the ratio of IR-A to total IR in endometrial carcinoma specimens were significantly higher than them in control endometrial tissue specimens (P<0.05). Further analysis indicated that the tendency was more prominently in patients with type 2 diabetes mellitus (T2DM) (table 2).

Overexpression of IR-A in RL95-2-CON cells
To investigate the role of IR-A in endometrial carcinogenesis and the potential interaction with T2DM signalling pathway, we synthesized stable RL95-2-CON cells that overexpressed IR-A because IR-A mRNA expression in the parental RL95-2-CON cell line is low. Full-length IR-A cDNA was cloned into the pcDNA3.1 eukaryotic expression plasmid (IR-A–pcDNA3.1) and used to construct the RL95-2-CON cell line stably overexpressing IR-A (RL95-2–IR-A).

The IR-A mRNA expression in one cloning of the RL95-2–IR-A stable cell line was determined to be 111.41 times higher

---

**Table 1.** Relative expression levels of IR and IR-A in endometrial cancer and control endometrial tissues.

|                | IR / GAPDH | IR-A / GAPDH | IR-A / IR |
|----------------|------------|--------------|-----------|
| endometrial cancer | 0.0188±0.0138 | 0.0127±0.0119 | 0.6296±0.1969 |
| Control endometrial tissues | 0.0138±0.0125 | 0.0085±0.0088 | 0.5021±0.1770 |
| *P* value     | <0.05      | <0.05        | <0.05    |

**Table 2.** Relative expression levels of IR and IR-A in endometrial cancer and control endometrial tissues from patients with type 2 diabetes mellitus.

|                | IR / GAPDH | IR-A / GAPDH | IR-A / IR |
|----------------|------------|--------------|-----------|
| endometrial cancer | 0.0222±0.0113 | 0.0148±0.0091 | 0.6819±0.1934 |
| Control endometrial tissues | 0.0160±0.0142 | 0.0091±0.0121 | 0.5391±0.1879 |
| *P* value     | <0.05      | <0.01        | <0.01    |

---

**Figure 2.** Expression of IR-A/ IR-B in endometrial carcinoma tissues and control normal endometrium tissues. A. Representative examples of the endometrial carcinoma tissues (total 103 cases). Lane M shown the DNA marker and Lanes T1–T19 correspond to 19 separate endometrial carcinoma patients B. Representative examples of control normal endometrium tissues (total 60 cases). Lanes N1–N25 correspond to 25 separate patients with normal endometrium.

**TABLE 1.** Relative expression levels of IR and IR-A in endometrial cancer and control endometrial tissues.

|                | IR / GAPDH | IR-A / GAPDH | IR-A / IR |
|----------------|------------|--------------|-----------|
| endometrial cancer | 0.0188±0.0138 | 0.0127±0.0119 | 0.6296±0.1969 |
| Control endometrial tissues | 0.0138±0.0125 | 0.0085±0.0088 | 0.5021±0.1770 |
| *P* value     | <0.05      | <0.05        | <0.05    |

**TABLE 2.** Relative expression levels of IR and IR-A in endometrial cancer and control endometrial tissues from patients with type 2 diabetes mellitus.

|                | IR / GAPDH | IR-A / GAPDH | IR-A / IR |
|----------------|------------|--------------|-----------|
| endometrial cancer | 0.0222±0.0113 | 0.0148±0.0091 | 0.6819±0.1934 |
| Control endometrial tissues | 0.0160±0.0142 | 0.0091±0.0121 | 0.5391±0.1879 |
| *P* value     | <0.05      | <0.01        | <0.01    |
than in parental cells by real-time RT-PCR and this cloning was used in the follow-up experiments.

**IR-A overexpression enhances cell proliferation**

To investigate the effect of IR-A overexpression on cell proliferation, we plotted 7-day growth curves for RL95-2–IR-A, RL95-2–CON and RL95-2–NC using OD490 nm values. The growth curves for RL95-2–CON and RL95-2–NC were similar, but IR-A overexpression significantly enhanced the proliferation of RL95-2–CON cells when plated 2000 cells/well starting cells(Figure 3A). According to OD490 nm values at 72 hours when plated different number of starting cells, we observed that IR-A overexpression can’t significantly enhanced the proliferation of RL95-2–CON cells when plated 10000 cells/well or more starting cells(Figure 3B).

**IR-A overexpression leads to increased cell division**

To determine whether the IR-A overexpression could influence the cell cycle progression of RL95-2–CON cells, flow cytometry was used to quantify the proportion of RL95-2–IR-A cells containing in S phase DNA content relative to controls. We found that 25.65% and 26.39% of RL95-2–CON and RL95-2–NC cells, respectively, were in contained S phase cells, but that this was increased to 35.04% in RL95-2–IR-A.
cells (Figure 4A, C). The proportion of RL95-2–IR-A cells containing S phase DNA content was significantly higher than controls ($P < 0.05$).

To further investigate the potential anti-apoptotic role of IR-A in endometrial carcinoma, we used a double labeling technique using Annexin-V and PI to distinguish between apoptotic and necrotic cells. The percentage of apoptotic cells was 5.47% and 5.32% in the RL95-2–CON and RL95-2–NC control cells, but was reduced to 4.59% in RL95-2–IR-A cells (Figure 4B, D). There was no significant difference of the percentage of apoptotic cells between RL95-2–IR-A and control cells ($P > 0.05$).

PI3K-Akt and ERK signaling are differentially regulated in cells overexpressing IR-A

As no IR-A specific antibodies are available, we confirmed that expression of IR-A protein was increased in RL95-2–IR-A cells by quantitating the total insulin receptor expression using an insulin receptor (IR) pan-specific antibody. As shown in Figure 5A, B, IR protein expression in RL95-2–IR-A cells was approximately three-fold higher than in either RL95-2–CON or RL95-2–NC cells.

The PI3K-Akt and ERK signaling plays a role in the regulation of various cellular processes such as proliferation, differentiation, development, survival and apoptosis [11]. So we measured phospho-ERK1/2, phospho-Akt and total ERK1/2 and Akt to detect the activation of these two signaling pathways. Total ERK1/2 and Akt protein expression were not affected by IR-A overexpression. However, levels of phospho-Akt were significantly increased in RL95-2–IR-A cells relative to controls, while levels of phospho-ERK1/2 were reduced (Figure 5C).

Inhibition of the PI3K–Akt pathway reverses the effects of IR-A overexpression

In order to confirm the results that IR-A -induced cell proliferation through PI3K/Akt pathway, we treat the RL95-2–IR-A cells with PI3K inhibitor (LY294002) [12]. Levels of phosphorylated Akt were reduced 48 h after treatment with 5, 10, 20 or 40 µM LY294002. Further, the proportion of RL95-2–IR-A cells in S phase was reduced and the proliferation rate of RL95-2–IR-A cells was reduced 48 h after treatment with 20 µM LY294002(Figure 6).

IR-A overexpression increases tumorigenicity of endometrial carcinoma cells

To explore whether IR-A overexpression in RL95-2-CON cells affects their tumorigenicity of nude mice xenografts, we injected RL95-2-IR-A, RL95-2-CON or RL95-2–NC cells into BALB/c nude mice and monitored tumor volumes every week for 5 weeks. As shown in Figure 7, there are subcutaneous tumor in all three group mice and the histology of tumours was endometrial carcinoma. RL95-2–IR-A xenografts developed larger tumors than those of RL95-2–CON and RL95-2–NC control cells, indicating that 1R-A overexpression exerts a
IR-A Overexpression in Endometrial Carcinomas

**Discussion**

In this study, we investigated the role of IR-A in endometrial carcinogenesis in vitro and in vivo. We found that IR-A is expressed at similar levels in normal endometrial tissues,

...strong tumor-promoting effect on endometrial carcinoma cells in vivo.

---

**Figure 5. Effect of IR-A overexpression on downstream signaling pathways.** A. Western blot analysis of IR protein expression and expression of downstream signaling proteins in RL95-2–CON, RL95-2–NC and RL95-2–IR-A cells. B. IR protein expression in RL95-2–IR-A cells is significantly higher than that in RL95-2–CON and RL95-2–NC cells. C. The relative expression of phospho-Akt is significantly increased and the relative expression of phosphorylated ERK1/2 reduced in RL95-2–IR-A cells than controls. *, #, P < 0.05 vs. control.

doi: 10.1371/journal.pone.0069001.g005

**Figure 6. PI3K inhibition reverses the effects of IR-A overexpression.** A. Western blot analysis of phospho-Akt and total Akt levels 48 h after treatment with 5, 10, 20 and 40 μM of LY294002. B. Growth curves of RL95-2–IR-A cells following treatment with 20 μM LY294002 and without. C. Flow cytometry analysis indicating the proportion of RL95-2–IR-A cells containing S phase DNA at 48 h after treatment with 20 μM LY294002. D. Flow cytometry analysis indicating the percentage of apoptotic cells in RL95-2–IR-A cells at 48 h after treatment with 20 μM LY294002. *, P < 0.05 vs. control.

doi: 10.1371/journal.pone.0069001.g006
endometrial carcinoma tissues and endometrial carcinoma cells. However, further analysis showed that IR-A expression was significantly higher in endometrial carcinomas from patients with T2DM than that in control patients. A number of epidemiological studies have demonstrated that type 2 diabetes mellitus (T2DM) is an important risk factor for many cancers, including endometrial carcinoma, although the molecular mechanism remains unclear [13]. The insulin receptor (IR) have been found to be overexpressed in cancer cells [14,15] and signaling through IR is increased in hyperinsulinemia [16]. Several studies have firmly established that IGF-2 elicits its biological effects through IR-A. For instance, IGF-2 is a more potent mitogen than insulin in mouse fibroblasts expressing only IR-A and not IGF-IR (R-/IR-A cells) [4].

Previous studies have also shown that endometrial carcinomas can express IGF-2 [17]. Interestingly, we confirmed that endometrial carcinoma cells, and particularly the RL95-2-CON cell line, secrete IGF-2 by RT-PCR and Elisa. Taken together, these data support that IR-A overexpression drives endometrial carcinogenesis, and we additionally propose that increased IGF-2 secretion in cells overexpressing IR-A may further stimulate the IR pathway.

Our study also shown that cell lines with overexpression of IR-A(RL95-2-IR-A) was successfully constructed and overexpression of IR-A showed a significant proliferation-promoting effect in vitro on RL95-2-CON cell lines which originally has a low expression level of IR-A. Flow cytometry analysis shown that one possible cause of cell growth faster in RL95-2–IR-A may be due to the DNA content in S phase increased. The xenotransplant nude mice model datas shown that the average tumor volume in RL95-2–IR-A xenotransplant mice group were significantly bigger than those in the control group indicating that the IR-A could increased the growth of RL95-2-CON cells in vivo. We discovered that the PI3K/Akt signaling pathway was activated and and the MAP kinase pathway was inactivated in cells overexpressing IR-A level, indicating that IR-A-mediated proliferation occurs through the PI3K/Akt signaling pathway and not the MAP kinase pathway. The PI3K/AKT axis regulates essential cellular functions including cell survival, proliferation, migration, and angiogenesis [18], the PI3K-Akt signaling pathway is implicated in human diseases including diabetes and cancer. Dysregulation and activation of the pathway is common in a large fraction of most human tumor types [19]. Further, PI3K-Akt pathway inhibition led to a reduction in Akt phosphorylation, a reduction in the proportion of cells in S phase and a reduction in growth rate of cells overexpressing IR-A. Our hypothesis may be perfect for that IR-A overexpression drives endometrial carcinogenesis through the PI3K/Akt signaling pathway.

In conclusion, IR-A expression in endometrial carcinoma patients with T2DM was significantly higher than that in patients without T2DM, and it is likely that IR-A overexpression can promote endometrial carcinoma cell proliferation. It is possible that the level of IR-A expression could make a significant contribution to cell growth and survival in endometrial carcinomas. However, the specific pathogenesis and molecular mechanism requires further investigation.
Materials and Methods

Reagents

CellTiter 96® AQueous One Solution Cell Proliferation Assay was purchased from Promega (USA). The Annexin V-FITC & PI Apoptosis Detection Kit was purchased from Beijing Puli Lai Gene Technology Co. Ltd (China). The anti-insulin receptor antibody was purchased from Abcam (Cambridge, UK); anti-phospho-p44/42 MAP Kinase (Thr202/Tyr204), anti-p44/42 MAPK, anti-phospho-Akt (Ser473), anti-Akt, anti β-actin and anti-rabbit IgG horseradish peroxidase (HRP)- conjugated antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). LY294002 was purchased from Invitrogen (Carlsbad, CA, USA).

Tissue samples and cell lines

With approval from the ethics committee for research involving Human Subjects of Peking University People’s Hospital and patients’ written informed consent, Samples of 103 endometrial carcinomas were obtained from patients treated with surgery in the Peking University People’s Hospital from November 2007 to July 2011. 18 of them are patients with type 2 diabetes mellitus (T2DM). 60 normal endometrial tissues were obtained from patients who received hysterectomy for early stage ovarian cancer or early stage Cervical Cancer during the same period. 9 of them are patients with T2DM. The tissue samples were immediately snap frozen and stored at liquid nitrogen. All endometrial carcinomas and normal endometrial tissues were review confirmed by two pathologists. The mean ages of patients with endometrial carcinomas and controls were 61 ± 11 years and 56± 14 separately. The difference was not statistically significant.

Ishikawa, HEC-1a, KLE and RL95-2-CON endometrial cancer cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA) and maintained in our laboratory. Breast cancer cell line MCF-7 was donated by Professor Mao Zebin in department of Biochemistry, Peking University Basic Medical School and Liver cancer cell line Hep-G2 was donated by Hepatobiliary Surgery Center of Peking University People’s Hospital, both of them was obtained from American Type Culture Collection initially. All cell lines were maintained under 5% CO₂ at 37° C and OD 490nm at 96h for RL95-2–CON, RL95-2–NC and IR-A Overexpression in Endometrial Carcinomas

Reverse transcription polymerase chain reaction (RT-PCR) and real-time RT-PCR

Total RNA was prepared from endometrial cancer cells and frozen tissue samples using Trizol reagent (Invitrogen, USA) and cDNA was synthesized from 2 µg total RNA using a QuantScript RT Kit (Tiangen, China), and used for PCR amplification. Two pairs of primers were used to amplify the insulin receptor isoforms. F1,5’-AGG CAG GGC GAA GAC AGT-3’ and R1,5’-GAT GGC ATA GCC CGT GAA-3’ amplified IR-A and IR-B mRNA fragments of 444 bp and 480 bp, respectively; F2,5’-AAC CAG AGT GAG TAT GAG GAT-3’ and R2,5’-CCG TTC CAG AGC GAA GTG CTT-3’, producing a 214 bp fragment. As a control, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was amplified using the primers F,5’-GAA GGT GAA GGT CGG AGT C-3’ and R,5’-GAAGATGGTGATGGGATTTC-3’, producing a 226 bp fragment.

To accurately quantify insulin receptor mRNA expression, IR-A, IR and GAPDH cDNAs were amplified using real-time PCR. Primers, probe and PCR Master Mix (GAPDH, IR-A, IR) were purchased from Applied Biosystems (USA). All reagents were kept on ice and the probe mix was kept in the dark. PCR conditions were: 50° C for 2 min, 95° C for 10 min, then 40 cycles of 92° C for 15 s and 60° C for 60 s. The comparative Ct method was used to calculate the relative differences in mRNA expression.

Enzyme-linked immunosorbent assay

IGF-2 protein secretion was measured in culture medium using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (R and D Systems). The detection limit of the kit is 15 pg/mL.

Construction of RL95-2-CON cell lines overexpressing IR-A

Full-length IR-A cDNA was amplified from the INSR-TOPO-XL (BC117172) plasmid using high-fidelity DNA polymerase, cloned into the pcDNA3.1 eukaryotic expression vector (Invitrogen, USA) and verified by restriction digest (two bands of the expected sizes, 5.5 kb and 4 kb) and sequencing. The IR-A–pcDNA3.1 plasmid was transformed into E. coli MAX DH10B and amplified, then transfected into RL95-2-CON cells using Lipofectamine 2000 (Invitrogen, USA). Stably transfected cell clone were done using G418 scanning. Western blot and RT PCR analysis for detecting IR-A protein and mRNA in stably transfected cell clone.

Stable cells clone containing IR-A–pcDNA3.1 were named RL95-2–IR-A; those containing empty pcDNA3.1 plasmid were named RL95-2–NC; and the parental cell line was named RL95-2-CON.

Cell proliferation

The MTS assay was used to generate 7-day growth curves and OD 490nm at 96h for RL95-2–CON, RL95-2–NC and RL95-2–IR-A cell lines, according to the protocol for the CellTiter 96® AQueous One Solution Cell Proliferation Assay. The proliferation rate of RL95-2–IR-A cells treated with 0 or 20 µM of the PI3K inhibitor LY294002 for 48 h was also established. Each treatment was administered to cells at the same time in six individual wells per experiment, and the experiments were repeated three times.

Flow cytometry

Cells (5 x 10⁶) were seeded into 6-well plates and incubated overnight in DMEM/F12 containing 10% FBS, and then
harvested for flow cytometry analysis as described previously [20]. Chilled ethanol (4 °C) was added to the cell suspension to a final concentration of 70% and incubated at 4 °C overnight. After washing, cells were resuspended in PBS and strained through a 400-µm mesh sieve (Wako, Osaka, Japan) to exclude cell aggregates. RNAse (100 µg/ml final concentration) was added to the cell suspension and incubated at 37 °C for 30 min in the dark. Cells were then stained with propidium iodide (PI; 100 µg/ml) in PBS for 30 min at room temperature. The DNA content of cell samples was measured using a FACSCalibur flow cytometer (Becton Dickinson, Mountain View, CA, USA). Apoptotic cells were detected according to the flow cytometry protocol of the Annexin V-FITC & PI Apoptosis Detection Kit (Beijing Biosea Biotechnology Co., Ltd, China) using a FACSCalibur flow cytometer.

Cell cycle progression was determined for RL95-2–IR-A cells treated with 0 or 20 µM of LY294002 for 48 h.

**Western blot analysis**

RL95-2–IR-A, RL95-2–NC and RL95-2–CON cells were harvested and protein extraction was performed as described previously [21]. Protein concentration was determined using a BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL, USA) according to the manufacturer’s instructions. Soluble protein (30 µg) was separated on a 10% SDS-PAGE gel, and then transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore, USA). Membranes were blocked by incubation with 5% skimmed milk in Tris-buffered saline (TBS-T) at room temperature for 2 h. Phosphorylated ERK1/2, total ERK1/2, phosphorylated Akt, total Akt and β-actin proteins were detected by incubating membranes overnight at 4 °C with the relevant antibodies (1:1000 dilution) in TBS-T containing 5% BSA. After washing three times for 5 min with TBS-T, membranes were incubated for 2 h at room temperature with HRP-conjugated secondary antibody (1:5000 dilution) in TBS-T containing 5% skimmed milk. Proteins were detected using the ECL Plus Western blotting detection system (GE Healthcare, Chalfont St. Giles, UK). Protein band intensity was measured using the MicroChemi chemiluminescence gel imaging system (Israel DNR).

RL95-2–IR-A were treated with 0, 5, 10, 20 or 40 µM LY294002 PI-3K inhibitor for 48 h, then phospho-Akt expression was measured by Western blotting

**Xenograft assay**

In vivo studies were performed in athymic nude mice to examine the tumorigenicity of control RL95-2-CON and IR-A-overexpressing cells. Female four-week-old BALB/c nude mice were obtained from the Beijing Vital River Laboratory Animal Technology Co Ltd (Certificate No: SCXK 2006-0008) and maintained in specific pathogen-free facilities approved by the Animal Care and Use Committee of Peking University People’s Hospital. Nude mice were randomly divided into three groups (five mice per group). RL95-2-IR-A, RL95-2-NC or RL95-2-CON cells (5×10⁶) were inoculated subcutaneously into the right flank of each mouse. Tumor growth was measured weekly using vernier calipers and tumor volume was calculated using the formula [4]: length (mm) × width² (mm²)/2. Animals were sacrificed five weeks post-inoculation. Tissue samples were harvested for histological analysis, fixed and embedded in paraffin wax, and 3 µm sections were cut.

**Statistical analysis**

All statistical analyses were performed using SPSS13.0 software (SPSS, Chicago, IL, USA). Comparisons among all cell groups were performed using one-way analysis of variance (ANOVA) and P-Values less than 0.05 was considered to be statistically significant. The Tukey’ post hoc test was used for samples where differences were statistically significant.

**Author Contributions**

Conceived and designed the experiments: XL LW. Performed the experiments: CW GZ. Analyzed the data: CW GZ LZ. Contributed reagents/materials/analysis tools: XL. Wrote the manuscript: CW GZ.

**References**

1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E et al. (2005) Endometrial cancer. Lancet. 366: 491-505. doi:10.1016/S0140-6736(05)67063-8. PubMed: 16084259.
2. Giudice LC, Lesko FC, Arndt-Jovin DJ, Jovin TM, Jares-Erijman EA (2011) Differential endocytosis and signaling dynamics of insulin receptor variants IR-A and IR-B. J Cell Sci 124: 801-811. doi: 10.1242/jcs.076869. PubMed: 21303927.
3. Moller DE, Yokota A, Caro JF, Flier JS (1989) Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol Endocrinol 3: 1263–1269. doi: 10.1210/mend-3-8-1263. PubMed: 1711052.
4. Denley A, Bonython ER, Booker GW, Cosgrove LJ, Forbes BE et al. (2004) Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Mol Endocrinol 18: 2502–2512. doi:10.1210/me.2004-0183. PubMed: 15205474.
5. Frasca F, Pandini G, Sciacca L, Mineo R, Vigneri R et al. (1999) Insulin receptor isoform-A, a newly recognized, insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19: 3278–3288. PubMed: 10207053.
6. Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R et al. (2002) A novel autocine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab 87: 245–254. doi: 10.1210/jc.87.1.245. PubMed: 11788654.
7. Kalli KR, Faloow OI, Bale LK, Zschunkne MA, Roche PC et al. (2002) Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. Endo-crinology 143: 3259–3267.
8. Sciacca L, Mineo R, Pandini G, Murabito A, Vigneri R et al. (2002) In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene 21: 8240–8250. doi:10.1038/sj.onc.1206058. PubMed: 12447687.
9. Denley A, Wallace JC, Cosgrove LJ, Forbes BE (2003) The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review. Horm Metab Res 35: 778–785. doi:10.1055/s-2004-814157. PubMed: 14710358.
10. Ulatan DB, Ludwig DL, Kahn CR, Hanahan D (2010) Insulin receptor functionally enhances multistage tumour progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proceedings of the National Academy of Sciences of the United States of America 107: 10791–10796. PubMed: 20457905.
11. Alvino CL, Ong SC, McNeil KA, Delaine C, Booker GW et al. (2011) Understanding the mechanism of insulin and insulin-like growth factor
12. Shaul YD, Seger R (2007) The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta 1773: 1213–1226. doi:10.1016/j.bbamcr.2006.10.005. PubMed: 17112607.

13. Lai JP, Sandhu DS, Yu C, Moser CD, Hu C et al. (2010) Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors. Liver Int 30: 1522–1528. doi:10.1111/j.1478-3231.2010.02336.x. PubMed: 21040406.

14. Hemminki K, Li X, Sundquist J, Sundquist K (2010) Risk of cancer following hospitalization for type 2 diabetes. Oncologist 15: 548-555. doi:10.1634/theoncologist.2009-0300. PubMed: 20479278.

15. Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D et al. (1990) Elevated insulin receptor content in human breast cancer. J Clin Invest 86: 1503–1510. doi:10.1172/JCI114868. PubMed: 2243127.

16. Gallagher EJ, LeRoith D (2010) The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 21: 610–618. doi:10.1016/j.tem.2010.05.007. PubMed: 20663667.

17. McGrath M, Lee IM, Buring J, De Vivo I (2011) Common genetic variation within IGF1, IGFII, IGFBP-1, and IGFBP-3 and endometrial cancer risk. Gynecol Oncol 120(2): 174-178. doi:10.1016/j.ygyno.2010.10.012. PubMed: 21078522.

18. Garrett JT, Chakrabarty A, Arteaga CL (2011) Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget 2: 1314-1321. PubMed: 22248929.

19. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296: 1655–1657. doi:10.1126/science.296.5573.1655. PubMed: 12040186.

20. Zhang G, Li X, Zhang L, Zhao L, Jiang J, Wang J et al. (2010) The expression and role of hybrid insulin/insulin-like growth factor receptor type 1 in endometrial carcinoma cells. Cancer Genet Cytogenet 200: 140–148. doi:10.1016/j.cancergencyto.2010.04.007. PubMed: 20620597.

21. Zhang L, Li X, Zhao L, Zhang L, Zhang G et al. (2009) Nongenomic effect of estrogen on the MAPK signaling pathway and calcium influx in endometrial carcinoma cells. J Cell Biochem 106(4): 553-562. doi: 10.1002/jcb.22017. PubMed: 19160418.